Clinical efficacy and safety of azithromycin sequential therapy combined with risk management in the treatment of mycoplasma pneumoniae pneumonia in children
Objective To explore the clinical efficacy and safety of azithromycin sequential therapy combined with risk management in the treatment of mycoplasmal pneumonia pneumonia(MPP)in children.Methods MPP children admitted to the Department of Pediatrics of Quzhou People's Hospital from March 2023 to November 2023 were retrospectively selected,and divided into a study group(azithromycin sequential therapy combined with risk management)and a control group(azithromycin sequential therapy combined with routine care)according to different intervention methods.The clinical efficacy,inflammatory cytokines[interleukin-6(IL-6),interleukin-17(IL-17),and tumor necrosis factor-α(TNF-α)],incidence of MPP-related complications,and incidence of drug-related adverse reactions(DRAR)in the two groups after treatment were observed and compared.Results A total of 119 children with MPP were included in the study,with 57 in the study group and 62 in the control group.The clinical efficacy of children with MPP in the study group was significantly higher than that in the control group(P＜0.05).There was no significant difference in IL-6,IL-17,and TNF-α between the two groups before treatment(P＞0.05);after treatment,both groups showed significant decreases in IL-6,IL-17,and TNF-α compared with before treatment,and these indicators of the study group were lower than thsoe of the control group(P＜0.05).The incidence of MPP-related complications in children in the study group was lower than that in the control group(P＜0.05),and there was no significant difference in the incidence of adverse drug reactions between the two groups(P＞0.05).In addition,the satisfaction of MPP children's family members in the study group with nursing care was significantly higher than that in the control group(P＜0.05).Conclusion The clinical efficacy of azithromycin sequential therapy combined with risk management in the treatment of pediatric MPP is significant,which can regulate the expression of inflammatory cytokines,reduce MPP-related complications,and improve clinical efficacy and family satisfaction with nursing care.
AzithromycinRisk managementMycoplasma pneumoniae pneumoniaInflammatory cytokinesDrug related adverse reactionsNursingSatisfaction
NETL
NSTL
万方数据
